

CERTIFICATE OF BIOSTATISTICS

20th, July 2018


To whom it may concern

Title of study: Loss of efficacy and safety of the switch from Infliximab Original to Infliximab Biosimilar (CT-P13) in patients with inflammatory bowel disease.

Chief investigator: Dr. Federico Argüelles Arias

Department of Gastroenterology, Virgen Macarena Hospital
Seville- Spain

I, Dr. Angel Vilches Arenas, Principal Professor in Preventive Medicine and Public Health in University of Seville- Spain, certifies that the statistical analysis of this article was performed and verified by myself and our Department. This certificate is delivered to the concerned person for any purposes for which it may be required.


Dr. Angel Vilches Arenas

Preventive Medicine and Public Health

Virgen Macarena Hospital/ University of Seville- Spain.

Email: ava@us.es

Address: Fedriani doctor S/N 41009. Telephone: +34 954551771

